<DOC>
	<DOCNO>NCT00987324</DOCNO>
	<brief_summary>The purpose randomize study determine treatment option , either paclitaxel-eluting balloon , paclitaxel-eluting stent plain balloon angioplasty effective treatment restenosis implantation `` Limus '' -eluting stent , ( LES ) .</brief_summary>
	<brief_title>Efficacy Study Paclitaxel-eluting Balloon , -Stent v . Plain Angioplasty Drug-eluting Stent Restenosis</brief_title>
	<detailed_description>The use drug-eluting stent ( DES ) lead drastic reduction restenosis rate compare bare metal stent ( BMS ) , 5 % 10 % patient receive DES still need revascularization treat vessel . Two important family drug use stent coating : paclitaxel belong taxane family , `` limus '' -family sirolimus , everolimus , zotarolimus , biolimus A9 pimecrolimus . Data regard optimal treatment in-DES-restenosis limited . Implanting new DES in-DES-restenosis report associated re-restenosis rate high 43 % . Several recent well publish study show substantial reduction restenosis use paclitaxel-eluting balloon ( PEB ) de-novo lesion BMS-restenotic lesion . The objective randomized trial ass hypothesis , PEB non-inferior paclitaxel-eluting-stents ( PES ) restenosis `` limus '' -eluting-stents ( LES ) , , PEB PES , superior plain angioplasty patient restenosis initial LES implantation .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients ischemic symptom evidence myocardial ischemia presence ≥ 50 % restenosis prior implantation LES native coronary vessel . 2 . Written , inform consent patient her/his legallyauthorized representative participation study . 3 . In woman childbearing potential negative pregnancy test mandatory . 1 . Age &lt; 18 year . 2 . Cardiogenic shock . 3 . Acute STelevation myocardial infarction within 48 hour symptom onset . 4 . Target lesion locate leave main trunk bypass graft . 5 . Target lesion locate small vessel ( vessel size &lt; 2.0 mm ) . 6 . Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le 12 month may result protocol noncompliance . 7 . Severe renal insufficiency ( glomerular filtration rate ≤ 30 ml/min ) . 8 . Contraindications antiplatelet therapy , paclitaxel , stainless steel , cobalt , chrome . 9 . Pregnancy ( present , suspected plan ) positive pregnancy test . 10 . Previous enrollment trial . 11 . Patient 's inability fully comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>